Biography for John Carroll
John D. Carroll is a biotech analyst with 34 years of prize-winning experience in journalism. Appointed editor of FierceBiotech in 2003, he has covered genomics, biotechnology, healthcare and other business topics for Managed Care, American Banker, Small Times, and Local Business.com, He has also contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and other leading publications. He spent six years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times. He enjoys hiking, traveling and spending time with his family. Carroll is based in Vermont and Texas and can be reached at email@example.com. Follow @JohnCFierce on Twitter.
Articles by John Carroll
Agios is banking a $20 million payment from Celgene for a deal to extend their collaboration on cancer metabolism--originally struck in 2010--by another year.
Tomorrow Merck will take its best shot at convincing a group of FDA advisers that its sublingual allergy pill Grastek deserves a place in the nation's pharmacies.
Amgen, Celgene and Eli Lilly joined forces with some prominent venture players to back a $26 million round for Sutro Biopharma, a San Francisco-based biotech which has been garnering some careful scrutiny for its work on antibodies.
After months of building investors' expectations for its Phase IIb study for the cancer conjugate aldoxorubicin as a potential first-line treatment for soft tissue sarcoma, the small-cap biotech CytRx today said that it found an 80% to 100% improvement in the progression-free survival rate for its new-and-improved chemotherapy drug compared to the original chemo, sending its shares up more than 70% in premarket trading.
AbbVie is rolling out its second snapshot of promising Phase III data for its hepatitis C cocktail, demonstrating that the vast majority of patients taking the therapy were cleared of the virus after 12 weeks of dosing.
The pharma giant is recruiting new patients while expanding the program with a new Phase III study for early-stage patients--without changing the dosing regimen.
Novo Nordisk noted today that the Danish Financial Supervisory Authority informed it of its decision to call in the cops after concluding that Novo Nordisk didn't obey the letter of the law as written in Section 27 (1) of the Danish Securities Trading Act.
Bristol-Myers Squibb will go into its Wednesday panel session for the lipodystrophy drug metreleptin with an agency review that offers a grudging concession on signs of efficacy for a subgroup of patients along with some serious questions about potential safety issues and a number of criticisms for the way the clinical trial program was designed and executed.
Swiss biotech startup Covagen landed a new round of venture backing today that could reach up to $63 million, enough to cover a Phase II program for its lead anti-inflammatory drug along with some follow-up work in oncology.
Novartis CEO Joe Jimenez says the pharma giant easily has enough cash on hand to keep the dividends flowing to investors while reserving up to $6 billion for new bolt-on buyouts. In an interview with the Swiss newspaper Schweiz am Sonntag, which was picked up by Reuters, Jimenez says that the sweet spot for deals lies in the $2 billion to $4 billion arena--modest for a company of that size.